Avantgen Develops Novel Human Antibodies to Diagnose SARS-COV-2 Infection and Treat COVID-19
April 21st, 2020
AVANTGEN ANNOUNCES THE RAPID IDENTIFICATION AND PROMISING INITIAL TESTING OF ANTIBODIES INTENDED TO DIAGNOSE SARS-COV-2 INFECTION AND TREAT COVID-19
SAN DIEGO, CA.–(BUSINESS WIRE). AvantGen, Inc., a privately-held San Diego-based biotechnology company and contract service provider, today announced it has identified and tested fully human synthetic antibodies (“mAbs”) against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2, the “novel Coronavirus”) that show promise for development as diagnostics for SARS-CoV-2 infection and therapeutics for Coronavirus Disease 2019 (COVID-19).
The World Health Organization (WHO) declared the Coronavirus outbreak as a pandemic on March 11, 2020. To date, about 2.5 million people have been infected across 210 countries and territories around the world. COVID-19, the disease caused by the virus SARS-CoV-2, can lead to pneumonia and Severe Acute Respiratory Syndrome. Patients infected by SARS-CoV-2 have shown a much higher mortality rate compared to patients infected by the influenza virus. For those patients who develop breathing problems and required hospitalization, the subsequent course of the illness is much more severe and protracted than for influenza.
Like many other researchers and organizations around the world, AvantGen is racing to create more effective diagnostics and therapeutics for COVID-19.
“When the United States Center for Disease Control and Prevention (CDC) warned the novel Coronavirus was beginning to spread at a community level in the US on February 24th, we decided to screen our yeast display fully human synthetic antibody libraries for unique antibodies, or mAbs, against the virus for therapeutic and diagnostic development, to help combat this outbreak”, said Dr. Xiaomin Fan, Founder, President and CEO of AvantGen, “Within 3-4 weeks, we were able to isolate hundreds of unique mAbs directed against the spike envelope protein of the SARS-CoV-2 virus and identified a subset that are able to block the spike protein binding to the receptor on human cells, Angiotensin Converting Enzyme -2 (ACE2)”.
Testing conducted by the Company in close collaboration with leading academic groups demonstrate that a panel of unique mAbs can effectively neutralize virus-induced cell-killing, also known as cytopathic effect (CPE). Among these neutralizing unique mAbs, some can block the spike protein from interacting with ACE2, while others do not block the interaction. The finding that two distinct groups of unique mAbs, with different binding sites on the spike protein can neutralize the virus paves a way for the development of a cocktail of mAbs comprising blocking and non-blocking neutralizing mAbs for potentially a more effective therapy.
A second set of unique mAbs have been isolated that are suitable for the development of a rapid point-of-care diagnosis of Coronavirus infection by detecting the SARS-CoV-2 spike protein in clinical samples, such as saliva. Such diagnostic kits can detect Coronavirus infection in a few minutes at a very early stage of infection and does not require sophisticated equipment, a major advantage over the current PCR based methods. The development of the rapid diagnostic kit is currently on-going with collaborators, whose exceptionally sensitive detetion materials and state-of-the art manufacturing technologies represent potential advantages over currently available methods.
“We are pleased to see the potent neutralizing activities of the unique mAbs as potential therapeutics, the suitability of other unique mAbs for a potentially improved Coronavirus diagnostic kit, and the progress we have made in such a short time frame. These developments also highlight the speed and quality of the mAbs we can discover with our robust platform that enables us to make our contribution to the fight against this pandemic”, said Dr. Fan.
AvantGen, Inc is a leader in the use of yeast display technology for antibody discovery and optimization. Founded by experts in the creation of antibody discovery and optimization platforms, AvantGen excels in the rapid generation of antibodies for therapeutic, diagnostic and research tool applications. The Company’s platforms include a robust yeast display system, large natural human antibody database, fully human synthetic antibody libraries comprised of over 100 billion antibody clones displayed by yeast cells, NK cell engager technology, flow cytometry-based and other screening technologies, as well as novel methodologies for rabbit monoclonal antibody generation.
For more information, visit www.avantgen.com.
Mark F. Kubik, Chief Business Officer